New PRECISIONheor-led Study Examines Challenges in Capturing Economic Burden of Cancer
Congratulations to Suepattra May-Slater and the PRECISIONheor team for their contributions to a impactful study just published in the journal MMS Policy and Practice. The paper, entitled: “Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method” outlines the challenges in truly capturing the economic burden of cancer for both patients and their caregivers.
On Demand: Cell & Gene Day
As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.
Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape, including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.
NOW ON DEMAND – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Join Precision launch expert veterans for a live webinar discussion of the critical elements of a personalized, integrated and sustainable launch strategy.
- Learn about key challenges to launch success
- Understand how to de-risk and optimize commercial launch planning by better aligning efforts and managing expectations
- Learn how integrating real-world data and innovative analytic models can better inform strategy and execution across stakeholders, for greater impact/effectiveness and efficiency
The discussion will conclude with a live Q&A.
Precision Drug Utilization Management: The Future of Oncology Medication Management
The exponential spending growth in oncology has resulted in myriad utilization management strategies by both payers and providers to control costs, especially drug costs. Precision’s Julianna Kula, Bruce Edelen, Ronald Schleif, Jeffrey Becker, Mark Urban, and Elizabeth Oyekan explore current and emerging drug utilization management strategies being employed to help curtail oncology costs without adversely impacting patient quality and outcomes.
Judge Strikes Down ‘Accumulator Rule,’ Ending Potential Threat to Patient Assistance
More pushback against copay programs likely on the horizon: Precision’s Ryan Cox and Reta Mourad, PharmD, FNTP discuss why a federal court’s decision striking down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs, as well as a recent pharma lawsuit against a maximizer company, could spur more states to take action of their own.
Rare Disease On Payer’s Minds
Orphan drugs for rare diseases are now frequently found in big pharma pipelines. Payers have had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline. Precision’s Phil Cyr and Erin Lopata weigh in on new ways to pay for them.
Judge Strikes Down CMS’s So-Called ‘Accumulator Rule’
A federal court recently struck down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs. Precision’s Ryan Cox and Reta Mourad weigh in on why the decision may spur more pushback against these copay programs.
The rise of virtual care: Implications across the health care continuum
The COVID-19 pandemic served as a catalyst for the expansion and uptake of telehealth and virtual care for office visits and outpatient care, which rose from less than 1% utilization in 2019 to more than 50% at the height of the pandemic in 2020. Now, as the pandemic stabilizes, virtual care visits have declined significantly and have largely stabilized at about 10% of health care visits. Precision’s Elizabeth Oyekan and Reta Mourad discuss three reasons that virtual care and telehealth care are here to stay.
MM&M’s Top 100 North American healthcare agencies of 2022
We are happy to announce that PRECISIONvalue and PRECISIONeffect have made the list of MM&M’s Top 100 North American healthcare agencies of 2022!
Court Decision on Accumulator Rule Could Encourage State Bans
A federal court recently struck down a CMS final rule slated to take effect in 2023 which would have required pharmaceutical manufacturers to ensure that financial assistance provided to patients goes only to patients and not to payers under their copay accumulator and maximizer programs. Despite the ruling, Precision’s Ryan Cox and Reta Mourad discuss how the renewed attention to these programs could spur more states to take action of their own against them.
